CD40LG and COVID-19: Nevertheless, keeping in mind the biological heterogeneity of PACS, severe COVID-19 patients can develop IgG and IgM antibodies against NETs, which can protect these structures against degradation by circulating DNase [221]; their persistence in survivors of severe COVID-19 who develop PACS may contribute to inflammatory PACS [222].